Skip to main content
xMedica

NCT07159763ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza…

Phase 310,000 participants sought211 sites6 countries

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-09-08; recorded start 2025-09-25
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA))
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 181 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 10,000 participants (target), run at 211 sites, across 6 countries.

How this score is built
  • Enrolment38/40

    10,000 participants (target)

  • Site count25/25

    181 sites

  • Country count7/15

    5 countries

  • Planned duration6/10

    Planned over about 20 months

  • Sponsor scale2/10

    Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has led 4 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406 (CD388) can help prevent the flu in people who are at higher risk of becoming seriously ill from influenza. Researchers want to find out if MK-1406 dosed at a single study visit can provide protection against influenza compared with placebo. The study will include adolescents and adults who may be more vulnerable to complications from influenza because of their age, health conditions, or weakened immune systems. Researchers will also evaluate the safety of MK-1406 and how well participants tolerate the study medicine.

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of MK-1406 (CD388) administered as a single dose via 3 subcutaneous (SC) injections in adult and adolescent participants who are at higher risk of developing complications from influenza.

Conditions

  • Influenza

Eligibility

Eligibility
SexAll
Ages12 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: Primary Stratum A (non-immunocompromised participants who have chronic stable medical conditions) and Primary Stratum B (participants who are immunocompromised either due to underlying disease or receipt of immunosuppressive medications) * Has negative rapid antigen tests for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prior to dosing at Day 1 * Weight is ≥ 40 kg Primary Stratum A only * Has a history of pulmonary disease * Has moderate to severe asthma, as defined by the Global Initiative for Asthma (GINA 2025) * Has existing cardiac disease * Has insulin-dependent diabetes * Has moderate renal impairment * Is ≥ 65 years of age at the time of randomization but does not meet any of the above criteria for Primary Stratum A, and is otherwise healthy Primary Stratum B only * Has a solid tumor diagnosis AND has received chemotherapy and/or immunotherapy within 1 year of screening * Has a diagnosis of a hematologic malignancy within 5 years of screening AND has received any chemotherapy or biologic therapy within 1 year of screening * Participants who have had a solid organ transplant (SOT) must satisfy all of the following: * Has received a kidney, liver, heart, or lung transplant more than 6 months prior to screening * Is currently receiving at least two immunosuppressive medications * Participants who have had a hematopoietic stem cell transplant (HSCT) must satisfy at least one of the following: * Has a history of hematopoietic stem cell transplantation (HSCT) (i.e., autologous, allogeneic, bone marrow, peripheral blood stem cell, tandem \[peripheral blood and marrow\]) within 1 year of screening * Has a history of non-autologous HSCT with graft-versus-host disease (GvHD) requiring active treatment with immunosuppressants (e.g., systemic corticosteroids ≥1 mg/kg at screening), regardless of the duration of time since HSCT * Is receiving immunosuppressive medicines * Has received chimeric antigen receptor-modified T-cell therapy * Has received B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab) within the 12 months prior to screening * Has a diagnosis of any primary immunodeficiency except immunoglobulin A (IgA) deficiency * Has advanced or untreated human immunodeficiency virus (HIV) infection Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to zanamivir (following administration of inhaled or intravenous formulations), monoclonal antibody (mAbs (including Fc domains)), or any of the components of CD388 or placebo * Has an acute (time-limited) or febrile (temperature ≥ 38.0°C \[≥ 100.4°F\]) illness within 7 days prior to planned dosing on Day 1 * Has severe chronic kidney disease (CKD) or is receiving hemodialysis * Receipt within the past 30 days or 5 half-lives (whichever is longer) or anticipated receipt of any drug or other biologic agent (e.g., mAbs) administered for the prevention or treatment of influenza * Has a clinically significant bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder) or medical history of significant bleeding or bruising following intramuscular or subcutaneous (SC) injections or venipuncture * Has previously enrolled in this study (CD388.SQ.3.06)

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposePREVENTION
MaskingQUADRUPLE (4)
Enrolment10,000 participants sought

Sponsor and collaborators

  • Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Sponsor

Arms and interventions

  • MK-1406EXPERIMENTAL

    Participants will receive 450 milligrams (mg) dose of MK-1406 (CD388) by subcutaneous (SC) injection.

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo by SC injection.

Interventions

  • Combination product MK-1406

    MK-1406 liquid for injection administered subcutaneously (SC)

  • Combination product Placebo

    MK-1406 matched liquid for SC injection

Outcome measures

  1. Primary outcome

    Number of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug

    Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of participants experiencing protocol-defined ILI occurring after administration of MK-1406 (CD388), with influenza infection confirmed by an RT-PCR+ result based on a NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.

    Time frame Up to approximately 24 weeks post dose

  2. Secondary outcome

    Number of participants with ≥1 Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with ≥1 AE will be assessed.

    Time frame Up to approximately Day 197

  3. Secondary outcome

    Number of Participants Who Discontinued from the Study Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued the study because of an AE will be assessed.

    Time frame Up to approximately Day 197

  4. Secondary outcome

    Number of Participants with Injection Site Reactions (ISRs)

    Participants will complete the injection site reaction questionnaire in the eDiary Day 1 through Day 8 following the study intervention administration to assess for reactogenicity, based on the US Food and Drug Administration (FDA) toxicity grading scale used for vaccine trials. Injection site reactions are graded on a scale from 1 to 5 where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe and Grade 4 is potentially life threatening. The injection-site reactions assessed are pain, tenderness, erythema/redness, and induration/swelling.

    Time frame Up to approximately Day 8 post dose

  5. Secondary outcome

    Number of Stratum B Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug

    Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of Stratum B ((immunocompromised participants) experiencing protocol-defined ILI occurring after administration of CD388, with influenza infection confirmed by an RT-PCR+ result based on an NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.

    Time frame Up to approximately 24 weeks post dose

  6. Secondary outcome

    Number of Participants with All-cause Hospitalization within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza

    Hospitalizations are defined as an overnight admission in a hospital or similar acute care facility, including emergency rooms due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration. Number of participants with all-cause hospitalization within 30 days after the onset of symptomatic influenza will be assessed.

    Time frame Up to 30 days after onset of symptomatic laboratory-confirmed influenza

  7. Secondary outcome

    Number of Participants with All-cause Mortality within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza

    Number of participants with mortality due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration will be determined.

    Time frame Up to 30 days after onset of symptomatic laboratory-confirmed influenza

  8. Secondary outcome

    Plasma Concentrations Following Administration of MK-1406 (CD388)

    Blood samples will be collected at multiple time points to assess the plasma concentrations of MK-1406.

    Time frame Day 1 (pre-dose), Day 29, and Day 197 post dose

  9. Secondary outcome

    Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADAs)

    The number of participants with confirmed anti MK-1406 antibodies post-baseline (i.e. treatment-emergent ADAs) will be determined via evaluation of blood samples collected at multiple time points.

    Time frame Day 1 (pre-dose), Day 29, and Day 197 post dose

  10. Secondary outcome

    Number of Participants with Treatment Boosted ADAs

    The number of participants with an increase in ADA titer over an initial positive baseline titer (i.e., treatment-boosted ADAs) will be determined will be determined via evaluation of blood samples collected at multiple time points.

    Time frame Day 1 (pre-dose), Day 29, and Day 197 post dose

Dates

Dates
Start dateSeptember 25, 2025 (actual)
Primary completionJuly 2, 2027 (estimated)
CompletionJuly 2, 2027 (estimated)
First postedSeptember 8, 2025 (actual)
Last updatedNovember 17, 2026
Results postedNot stated in the registry record
Status last verifiedNovember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

93 sites are recruiting

Argentina

Argentina
FacilityCityState or regionStatus
CINME - Centro de Investigaciones Metabólicas ( Site 0007)Buenos AiresBuenos Aires F.D.Active, not recruiting
Centro de Estudios Infectológicos S.A. ( Site 0002)CABABuenos AiresActive, not recruiting
Equipo Ciencia ( Site 0008)Ciudad Autonoma de Buenos AiresBuenos AiresActive, not recruiting
Sanatorio Mayo Privado S.A ( Site 0003)CórdobaCórdoba ProvinceActive, not recruiting
Centro Medico de Enfermedades Respiratorias ( Site 0005)FloridaBuenos AiresActive, not recruiting
Instituto del Buen Aire ( Site 0006)Santa FeActive, not recruiting

Australia

Australia
FacilityCityState or regionStatus
Emeritus Research ( Site 0106)BotanyNew South WalesActive, not recruiting
Core Research Group ( Site 0102)BrisbaneQueenslandActive, not recruiting
Emeritus Research ( Site 0101)CamberwellVictoriaActive, not recruiting
Australian Clinical Research Network ( Site 0103)MaroubraNew South WalesActive, not recruiting
The AIM Centre Hunter Diabetes Centre ( Site 0105)NewcastleNew South WalesActive, not recruiting
Momentum St Leonards ( Site 0107)St LeonardsNew South WalesActive, not recruiting
Momentum Clinical Research Taringa ( Site 0104)TaringaQueenslandActive, not recruiting

Japan

Japan
FacilityCityState or regionStatus
Takeuchi Hospital ( Site 0818)Arakawa CityTokyoRecruiting
Ishikawa Prefectural Central Hospital ( Site 0814)KanazawaIshikawa-kenRecruiting
Medical Corporation Chiyukai Shin Komonji Hospital ( Site 0820)KitakyushuFukuokaRecruiting
National Hospital Organization Tokyo National Hospital ( Site 0802)KiyoseTokyoRecruiting
National Hospital Organization Kumamoto Medical Center ( Site 0801)KumamotoRecruiting
Jobu Hospital for Respiratory Diseases ( Site 0821)MaebashiGunmaRecruiting
Maebashi Hirosegawa Clinic ( Site 0804)MaebashiGunmaRecruiting
National Hospital Organization Tokyo Medical Center ( Site 0807)Meguro CityTokyoRecruiting
Association of Healthcare Corporation Oyama East Clinic ( Site 0823)OyamaTochigiRecruiting
NewHeart Watanabe Institute ( Site 0811)SuginamiTokyoRecruiting

South Africa

South Africa
FacilityCityState or regionStatus
Josha Research ( Site 0216)BloemfonteinFree StateActive, not recruiting
Madibeng Centre for Research ( Site 0201)BritsNorth WestActive, not recruiting
TREAD Research ( Site 0206)Cape TownWestern CapeActive, not recruiting
TASK Applied Science - Headquarter ( Site 0211)Cape TownWestern CapeActive, not recruiting
Tiervlei Trial Centre ( Site 0204)Cape TownWestern CapeActive, not recruiting
Centre for the Aids Programme of Research in South Africa. CAPRISA ( Site 0220)DurbanKwaZulu-NatalActive, not recruiting
Synergy Biomed Research Institute ( Site 0218)East LondonEastern CapeActive, not recruiting
Ubuntu Clinical Research Center ( Site 0208)JohannesburgGautengActive, not recruiting
Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0205)JohannesburgGautengActive, not recruiting
Qhakaza Mbokodo Research Clinic ( Site 0215)LadysmithKwaZulu-NatalActive, not recruiting
Newtown Clinical Research Centre ( Site 0207)NewtownGautengActive, not recruiting
Paarl Research Centre ( Site 0213)PaarlWestern CapeActive, not recruiting
Jose Pearson TB Hospital ( Site 0202)Port ElizabethEastern CapeActive, not recruiting
Global Clinical Trials ( Site 0212)PretoriaGautengActive, not recruiting
Emmed Research Incorporating ( Site 0209)PretoriaGautengActive, not recruiting
Jongaie Research ( Site 0214)Pretoria WestGautengActive, not recruiting
Aurum Institute - Rustenburg ( Site 0203)RustenburgNorth WestActive, not recruiting
Welkom Clinical Trial Centre ( Site 0219)WelkomFree StateActive, not recruiting

United Kingdom

United Kingdom
FacilityCityState or regionStatus
Aberdeen Royal Infirmary ( Site 0423)AberdeenAberdeen CityRecruiting
Birmingham Heartlands Hospital ( Site 0440)BirminghamRecruiting
Queen Elizabeth Hospital ( Site 0411)BirminghamActive, not recruiting
Layton Medical Centre ( Site 0405)BlackpoolLancashireRecruiting
Bradford Royal Infirmary ( Site 0444)BradfordRecruiting
Royal Sussex County Hospital ( Site 0443)BrightonBrighton And HoveRecruiting
Southmead Hospital ( Site 0409)BristolBristol, City ofActive, not recruiting
Velocity Clinical Research, Bristol ( Site 0428)BristolBristol, City ofRecruiting
University Hospital of Wales ( Site 0420)CardiffWalesActive, not recruiting

161 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 13, 2026

    Completion date moved later

    Primary completion delayed 2 days

    2027-06-302027-07-02

  2. November 6, 2026

    Site added

    26 sites added (211 total)

    185211

  3. October 27, 2026

    Site added

    4 sites added (185 total)

    181185

  4. October 15, 2026

    Site removed

    181 sites removed (181 total)

    362181

  5. October 15, 2026

    Status changed

    Status changed from Active not recruiting to Recruiting

    ACTIVE_NOT_RECRUITINGRECRUITING

  6. October 15, 2026

    Recruitment opened

    Recruitment opened

    ACTIVE_NOT_RECRUITINGRECRUITING

  7. September 17, 2026

    Completion date moved later

    Primary completion delayed 29 days

    2027-06-012027-06-30

  8. September 17, 2026

    Site added

    181 sites added (362 total)

    181362